Compare Amylx Pharmaceuticals Inc (AMLX) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Chipotle Mexican Grill, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.18 (market cap $1.98B), while Chipotle Mexican Grill, Inc. trades at $36.43 (market cap $45.22B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 22.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| AMLX | CMG | |
|---|---|---|
Market Cap | $1.98B | $45.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $56.00 |
52-Week Low | $7.64 | $28.17 |
Enterprise Value | $1.70B | $49.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Chipotle Mexican Grill (CMG) trades at $35.25, up 1.88% on the day, with strong analyst support and consistent earnings beats. The stock shows bullish technical signals with support at $34 and resistance at $35. Revenue grew to $11.93 billion in 2025, with a net income margin of 11.96%, though margins have narrowed slightly from prior years. Recent news highlights operational focus and menu innovation as growth drivers.
Outlook remains positive with a $40.46 consensus price target, but risks include cost pressures and competitive threats. The stock offers growth potential through expansion and operational excellence, yet investors should monitor margin trends and consumer spending shifts in the volatile restaurant sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
